• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Hospitalization expenses of acute ischemic stroke patients with atrial fibrillation relative to those with normal sinus rhythm.
CONCLUSION: AIS patients with AF incurred higher expenses during hospitalization compared with those with normal SR, due to greater stroke severity, higher rates of pulmonary infection and congestive heart failure, and longer hospital stays. PMID: 27559816 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - August 26, 2016 Category: Health Management Tags: J Med Econ Source Type: research

Clinical and economic impact of rivaroxaban on the burden of atrial fibrillation: the case study of Japan.
CONCLUSIONS: Introducing rivaroxaban may decrease the burden of NVAF in Japanese society. From a clinical perspective, the reduction in IS and embolic events outweighs the increased risk of anticoagulant-related bleeding; from an economic perspective, reduced event costs offset drug and physician visit costs, resulting in cost savings. PMID: 27112188 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - April 27, 2016 Category: Health Management Tags: J Med Econ Source Type: research

Estimation of the cost-effectiveness of apixaban versus vitamin K antagonists in the management of atrial fibrillation in Argentina
Abstract Apixaban, a novel oral anticoagulant which has been approved for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation, reduces both ischemic and haemorrhagic stroke and produces fewer bleedings than vitamin K antagonist warfarin. These clinical results lead to a decrease in health care resource utilization and, therefore, have a positive impact on health economics of atrial fibrillation. The cost-effectiveness of apixaban has been assessed in a variety of clinical settings and countries. However, data from emergent markets, as is the case of Argentina, are still scarce. ...
Source: Health Economics Review - June 26, 2015 Category: Global & Universal Source Type: research

Abstract 257: A Long-Term Comparison of Clinical and Economic Outcomes with Novel Oral Anti- Coagulants Session Title: Poster Session II
Conclusions: While using NOACs in NVAF treatment raises drug costs compared to current practice, it also reduces stroke incidence. Among NOACs, apixaban does so at lower cost, with fewer bleeding events than either dabigatran or rivaroxaban.
Source: Circulation: Cardiovascular Quality and Outcomes - June 2, 2014 Category: Cardiology Authors: Van Nuys, K., Kuznik, A., Phatak, H., Iloeje, U., Sullivan, J., Lakdawalla, D. N., Vasudeva, E., Weintraub, W. Tags: Session Title: Poster Session II Source Type: research

Review of Economics and Cost-Effectiveness Analyses of Anticoagulant Therapy for Stroke Prevention in Atrial Fibrillation in the US.
CONCLUSIONS: This review identified several areas of uncertainty regarding the economic benefit of anticoagulants. The generalizability of cost-effectiveness results of anticoagulant therapy in AF based on clinical trial data must be confirmed by comparative effectiveness research conducted in the real-world setting. PMID: 23606551 [PubMed - in process]
Source: The Annals of Pharmacotherapy - May 1, 2013 Category: Drugs & Pharmacology Authors: von Schéele B, Fernandez M, Hogue SL, Kwong WJ Tags: Ann Pharmacother Source Type: research

Pages: 1  2